Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Pandox in connection with a directed share issue of approximately SEK 3 billion
Mandate

Vinge has advised Pandox in connection with a directed share issue of approximately SEK 3 billion

November 06, 2019 Capital Markets and Public M&A

Vinge has advised the hotel property owner Pandox in connection with a directed share issue of 16,350,000 class B shares, whereby Pandox will receive approximately SEK 3 billion in issue proceeds.

The subscription price was determined to SEK 186.50 per share through an accelerated book building process. The share issue was directed to approximately 130 Swedish and international institutional investors. The purpose of the share issue is increase the financial flexibility for additional acquisitions and further strengthen the company’s competitive position in the international hotel property market.

Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Hampus Olsson.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026